Condition

Myelofibrosis (2)

Post-ET Myelofibrosis (2)

Post-PV MF (2)

Primary Myelofibrosis (2)

Overall Status

Recruiting (2)

Sign in for free

Phase

phase 1/phase 2 (2)

Sponsor

Kartos Therapeutics, Inc. (1)

Telios Pharma, Inc. (1)

Collaborator

Telios Pharma, Inc. (1)

Intervention

tl-895 (2)

krt-232 (1)

ruxolitinib (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

Post-ET Myelofibrosis

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Myelofibrosis, Primary Myelofibrosis, Post-PV MF Trial in Canton (TL-895, Ruxolitinib)

Recruiting

Myelofibrosis
+3 more

Birmingham, Alabama
+13 more

Jan 10, 2023

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis Trial in Worldwide (KRT-232, TL-895)

Recruiting

Myelofibrosis
+3 more

Birmingham, Alabama
+36 more

May 5, 2022